Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

被引：7
|
作者：
Coulter, Jonathan B. [1 ]
Easwaran, Hariharan [2 ]
机构：
[1] Johns Hopkins Univ, Brady Urol Inst, Sch Med, Baltimore, MD USA
[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Canc Genet & Epigenet, Oncol,Sch Med, Baltimore, MD 21231 USA
来源：
PLOS BIOLOGY | 2023年 / 21卷 / 04期
关键词：
POLYCOMB;
D O I：
10.1371/journal.pbio.3002081
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer
    Shankar, Eswar
    Franco, Daniel
    Iqbal, Omair
    Moreton, Stephen
    Kanwal, Rajnee
    Gupta, Sanjay
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 404
  • [2] Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer
    Han, Zhengyang
    Rimal, Ujjwal
    Khatiwada, Prabesh
    Brandman, Jacob
    Zhou, Jun
    Hussain, Muhammad
    Viola, Ronald E.
    Shemshedini, Lirim
    ENDOCRINOLOGY, 2022, 164 (01)
  • [3] Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer
    Bai, Yunfeng
    Zhang, Zhuangzhuang
    Cheng, Lijun
    Wang, Ruixin
    Chen, Xiaoliang
    Kong, Yifan
    Feng, Feng
    Ahmad, Nihal
    Li, Lang
    Liu, Xiaoqi
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (25) : 9911 - 9923
  • [4] Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
    Wu, Changping
    Jin, Xin
    Yang, Jing
    Yang, Yinhui
    He, Yundong
    Ding, Liya
    Pan, Yunqian
    Chen, Shuai
    Jiang, Jingting
    Huang, Haojie
    ONCOTARGET, 2016, 7 (03) : 3430 - 3442
  • [5] Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
    Labaf, Maryam
    Li, Muqing
    Ting, Lily
    Karno, Breelyn
    Zhang, Songqi
    Gao, Shuai
    Patalano, Susan
    Macoska, Jill A. A.
    Zarringhalam, Kourosh
    Han, Dong
    Cai, Changmeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response
    Fischetti, Irene
    Botti, Laura
    Sulsenti, Roberta
    Cancila, Valeria
    Enriquez, Claudia
    Ferri, Renata
    Bregni, Marco
    Crivelli, Filippo
    Tripodo, Claudio
    Colombo, Mario P.
    Jachetti, Elena
    EPIGENOMICS, 2024, 16 (09) : 653 - 670
  • [7] Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer
    Burkhart, Deborah L.
    Morel, Katherine L.
    Wadosky, Kristine M.
    Labb, David P.
    Galbo, Phillip M.
    Dalimov, Zafardjan
    Xu, Bo
    Loda, Massimo
    Ellis, Leigh
    CANCER PREVENTION RESEARCH, 2020, 13 (12) : 979 - 988
  • [8] The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer
    Yu, J.
    Cao, Q.
    Yu, J.
    Wu, L.
    Dallol, A.
    Li, J.
    Chen, G.
    Grasso, C.
    Cao, X.
    Lonigro, R. J.
    Varambally, S.
    Mehra, R.
    Palanisamy, N.
    Wu, J. Y.
    Latif, F.
    Chinnaiyan, A. M.
    ONCOGENE, 2010, 29 (39) : 5370 - 5380
  • [9] EZH2: a novel target for cancer treatment
    Duan, Ran
    Du, Wenfang
    Guo, Weijian
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [10] EZH2 accompanies prostate cancer progression
    Xin, Li
    NATURE CELL BIOLOGY, 2021, 23 (09) : 934 - 936
12345